Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accounts Payables (2016 - 2026)

United Therapeutics' Accounts Payables history spans 17 years, with the latest figure at $488.0 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 41.65% to $488.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $488.0 million, a 41.65% increase, with the full-year FY2025 number at $488.0 million, up 41.65% from a year prior.
  • Accounts Payables hit $488.0 million in Q4 2025 for United Therapeutics, up from $468.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for UTHR hit a ceiling of $488.0 million in Q4 2025 and a floor of $165.0 million in Q1 2021.
  • Historically, Accounts Payables has averaged $290.5 million across 5 years, with a median of $295.0 million in 2023.
  • Biggest five-year swings in Accounts Payables: decreased 6.63% in 2021 and later surged 51.48% in 2023.
  • Tracing UTHR's Accounts Payables over 5 years: stood at $174.6 million in 2021, then surged by 31.67% to $229.9 million in 2022, then rose by 29.62% to $298.0 million in 2023, then grew by 15.6% to $344.5 million in 2024, then surged by 41.65% to $488.0 million in 2025.
  • Business Quant data shows Accounts Payables for UTHR at $488.0 million in Q4 2025, $468.0 million in Q3 2025, and $432.0 million in Q2 2025.